Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion type Assertion NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_head.
- NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion description "[In recent years, the development of GCGR antisense oligonucleotides and small molecular weight GCGR antagonists have been pursued as possible therapeutic agents to target glucagon action as a treatment for Type 2 diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_provenance.
- NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion evidence source_evidence_literature NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_provenance.
- NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion SIO_000772 15948676 NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_provenance.
- NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion wasDerivedFrom befree-20140225 NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_provenance.
- NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_assertion wasGeneratedBy ECO_0000203 NP466799.RAMs0njK7vMl5QSL4ukyLSbrWXOI02iZ4LVMkJA5Ch1Y0130_provenance.